ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.…
ProKidney Names Farah Ali, M.D., M.S., Chief Medical Officer
ProKidney (NASDAQ: PROK) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 231 employees.
The shares were at 1.040 USD on 20 November 2026, down 63.0% over 52 weeks. Its 52-week range is 0.8702 USD to 2.950 USD: the price is 64.7% below the high and 19.5% above the low.
Its market capitalisation is 415.21M USD.
ProKidney reports return on equity of 6.8% and revenue down 19.8% year over year.
It holds more cash than debt, a net cash position of 138.61M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. The next earnings report is expected on 17 March 2027.